newsfilter
← Latest News
Business Wire·

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties ---- Ex-U.S. royalties remain unchanged --Xencor, Inc. (NASDAQ:XNCR) ("Xencor"), a clinical-stage biopharmaceutical